Table 1. Patient and lesion characteristics and treatment details.
Complete follow-up rate: 100% | N=66 |
---|---|
Observation period, months | 51 (7–103) |
Age, years | 67 (45–82) |
Sex | |
Male | 61 (92) |
Female | 5 (8) |
Synchronous double cancers | 13 (20) |
Head and neck cancer | 8 (12) |
Gastric cancer | 5 (8) |
Others | 3 (5) |
Tumor location | |
Cervix | 3 (5) |
Upper thorax | 12 (18) |
Middle thorax | 35 (52) |
Lower thorax | 15 (23) |
Abdomen | 1 (2) |
Endoscopic resection | |
EMRC | 12 (18) |
ESD | 54 (82) |
Vertical resection margin | |
Positive | 5 (8) |
Negative | 61 (92) |
Pathological tumor depth | |
Lamina propria mucosae | 5 (8) |
Muscularis mucosae | 18 (27) |
SM1 | 8 (12) |
SM2 or deeper | 35 (53) |
Lymphovascular involvement | |
Positive | 36 (55) |
Negative | 30 (45) |
Chemotherapy | |
Standard-dose CF | 58 (88) |
Low-dose CF | 6 (9) |
Others | 2 (3) |
Radiation dose, Gy | |
40.0 | 55 (83) |
41.4 | 5 (8) |
50.0 | 4 (6) |
60.0 | 2 (3) |
CF, cisplatin and 5-fluorouracil; EMRC, endoscopic esophageal mucosal resection using a cap-fitted panendoscope; ESD: endoscopic submucosal dissection; SM1, submucosa up to 0.2 mm from muscularis mucosae; SM2, submucosa deeper than 0.2 mm from muscularis mucosae.
Data are presented as median (range) or n (%).